Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

被引：0
|
作者：
Ketil A. Camilio
Meng-Yu Wang
Brynjar Mauseth
Stein Waagene
Gunnar Kvalheim
Øystein Rekdal
Baldur Sveinbjørnsson
Gunhild M. Mælandsmo
机构：
[1] Institute for Cancer Research,Department of Tumor Biology
[2] Oslo University Hospital,Department of Cellular Therapy
[3] Oslo University Hospital,Department of Medical Biology
[4] Lytix Biopharma AS,Division of Cancer, Surgery and Transplantation
[5] The Arctic University of Norway,Institute of Clinical Medicine
[6] Oslo University Hospital,undefined
[7] University of Oslo,undefined
[8] Oslo Cancer Cluster Incubator,undefined
来源：
Breast Cancer Research | / 21卷
关键词：
Triple-negative breast cancer; Immunochemotherapy; Combination therapy; Immunotherapy; Oncolytic peptide; LTX-315; Doxorubicin; DAMPs; ICD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Promising therapeutic options in triple-negative breast cancer
    Bilici, A.
    Arslan, C.
    Altundag, K.
    JOURNAL OF BUON, 2012, 17 (02): : 209 - 222
  • [42] Advances in Therapeutic Approaches for Triple-Negative Breast Cancer
    Mahtani, Reshma
    Kittaneh, Muaiad
    Kalinsky, Kevin
    Mamounas, Eleftherios
    Badve, Sunil
    Vogel, Charles
    Lower, Elyse
    Schwartzberg, Lee
    Pegram, Mark
    CLINICAL BREAST CANCER, 2021, 21 (05) : 383 - 390
  • [43] Model selection for assessing the effects of doxorubicin on triple-negative breast cancer cell lines
    Resende, Anna Claudia M.
    Lima, Ernesto A. B. F.
    Almeida, Regina C.
    McKenna, Matthew T.
    Yankeelov, Thomas E.
    JOURNAL OF MATHEMATICAL BIOLOGY, 2022, 85 (6-7)
  • [44] Model selection for assessing the effects of doxorubicin on triple-negative breast cancer cell lines
    Anna Claudia M. Resende
    Ernesto A. B. F. Lima
    Regina C. Almeida
    Matthew T. McKenna
    Thomas E. Yankeelov
    Journal of Mathematical Biology, 2022, 85
  • [45] An In Vitro Model of Triple-Negative Breast Cancer
    Russo, J.
    Su, Y.
    HUMAN CELL TRANSFORMATION: ADVANCES IN CELL MODELS FOR THE STUDY OF CANCER AND AGING, 2019, 1164 : 35 - 46
  • [46] Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer
    McArthur, Heather
    ONCOLOGY-NEW YORK, 2019, 33 (04): : 137 - 140
  • [47] Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
    Tang, Tianyu
    Huang, Xing
    Zhang, Gang
    Lu, Minghao
    Hong, Zhengtao
    Wang, Meng
    Huang, Junming
    Zhi, Xiao
    Liang, Tingbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [48] Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer
    Bellavita, Rosa
    Piccolo, Marialuisa
    Leone, Linda
    Ferraro, Maria Grazia
    Dardano, Principia
    De Stefano, Luca
    Nastri, Flavia
    Irace, Carlo
    Falanga, Annarita
    Galdiero, Stefania
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2024, 19 : 6057 - 6084
  • [49] Potential Combination Therapy for Triple-Negative Breast Cancer
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (06) : 1279 - 1279
  • [50] Triple-negative breast cancer and the potential for targeted therapy
    Jhan, Jing-Ru
    Andrechek, Eran R.
    PHARMACOGENOMICS, 2017, 18 (17) : 1595 - 1609
12345